Now live: Pro — the full 13F research suite for serious investorsSee pricing →
a16z Capital Management, L.L.C.

Q4 2024 · 13F-HR

a16z Capital Management, L.L.C.holdings as filed

Filed 2025-02-12 · accession 0001104659-25-012178

$745.3M
Reported value
12
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
25809K105DASHDOORDASH INC$267.9M35.9%1,597,010CommonSOLE
79589L106IOTSAMSARA INC$174.6M23.4%3,995,652CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$120.2M16.1%2,748,523CommonSOLE
852234103XYZBLOCK INC$86.4M11.6%1,016,697CommonSOLE
63909J108NAUTNAUTILUS BIOTECHNOLOGY INC$29.7M3.98%17,653,917CommonSOLE
09077V100BIOABIOAGE LABS INC$18.7M2.51%3,233,170CommonSOLE
00437E102ACCDUSDACCOLADE INC$18.5M2.48%5,398,708CommonSOLE
13463J101CAMPCAMP4 THERAPEUTICS CORP$11.1M1.49%2,125,339CommonSOLE
683712103OPENOPENDOOR TECHNOLOGIES INC$9.9M1.33%6,200,821CommonSOLE
29479A108ERASERASCA INC$7.2M0.96%2,862,500CommonSOLE
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$1.1M0.14%108,568CommonSOLE
23257B206CYNGN INC$48,8950.01%57,584CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.